Cirrus Pharmaceuticals Adds cGMP Suite

Article

Facility will provide manufacturing services for inhalation, liquids, topicals and oral solids dosage forms

Pharmaceutical contract development and manufacturing services provider Cirrus Pharmaceuticals, a Kemwell company, has announced that it will invest in a flexible cGMP suite in its facility in Research Triangle Park, NC. The addition of the suite will allow the company to offer cGMP manufacturing services for inhalation, liquids, topicals and oral solids dosage forms. The facility is scheduled to be operational in April 2015.

Kemwell’s R&D division employs 175 scientists worldwide and provides formulation development, analytical development, validation and clinical trial manufacturing.

Source: Cirrus Pharmaceuticals, a Kemwell company

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content